Compatibility of parenteral nutrition with drugs;Compatibilidad de fármacos con nutrición parenteral

Farmacia Hospitalaria

Volumn 24, Issue 5, 2000, Pages 332-344

  Del Hoyo Gil, L ^a   Serrano Garrote, O ^a   Gomis Munoz P ^a   Herreros de Tejada, A ^a  

^a HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

Author keywords

Compatibility; Drugs; Parenteral nutrition; Stability

Indexed keywords

ACETAZOLAMIDE; ACICLOVIR; AMIKACIN; AMINOPHYLLINE; AMOXICILLIN; AMPHOTERICIN B; AMPICILLIN; ATRACURIUM; AZTREONAM; BICARBONATE; BUMETANIDE; BUPRENORPHINE; BUTORPHANOL; CARBENICILLIN; CARBOPLATIN; CEFALOTIN; CEFAMANDOLE; CEFAPIRIN; CEFAZOLIN; CEFEPIME; CEFONICID; CEFOPERAZONE; CEFOTAXIME; CEFOTETAN; CEFOXITIN; CEFRADINE; CEFSULODIN; CEFTAZIDIME; SULTAMICILLIN; UNINDEXED DRUG;

AMINO ACID COMPOSITION; DRUG STABILITY; FOOD DRUG INTERACTION; LIPID COMPOSITION; PARENTERAL NUTRITION; REVIEW; TEMPERATURE;

EID: 0034490653     PISSN: 11306343     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (82)

1. Compatibility of neonatal parenteral nutrient solutions with selected intravenous drugs
2. Compatibility of medications with 3-in-1 parenteral nutrition admixtures
3. Issues in contemporary drug delivery. Part V: Total parenteral nutrition
4. Estabilidad de antibióticos administrados en Y con una mezcla de nutrición parenteral enriquecida en aminoácidos de cadena ramificada. Parte I: Amikacina y gentamicina
5. Guía práctica para la administración de fármacos con la nutrición parenteral
6. Compatibility of parenteral nutrient solutions with selected drugs during simulated Y-site administration
7. Visual compatibility of 30 additives with a parenteral nutrient solution
8. Visual compatibility of total parenteral nutrition solution (Synthamin 17 Premix®) with selected drugs during simulated Y-site injection
9. Stability of aminophylline injection in three parenteral nutrition solutions
10. Intravenous aminophylline: In vitro stability in fat-containing TPN
11. Compatibility of antibiotics and other drugs in total parenteral nutrition solutions
12. Piggyback compatibility of antibiotics with pediatric parenteral nutrition solutions
13. Compatibility considerations in parenteral nutrient solutions
14. Incompatibilidades entre medicamentos y mezclas de nutrición parenteral
15. Analysis of antibiotic stability in a parenteral nutrition solution
16. Antibiotic stability in a pediatric parenteral alimentation solution
17. Compatibility and availability of sodium bicarbonate in total parenteral nutrient solutions
18. Stability of caffeine injection in intravenous admixtures and parenteral nutrition solutions
19. Compatibility of total nutrient admixtures and secondary antibiotic infusions
20. Stability of ampicillin, piperacillin, cefotaxime, netilmicin and amikacin in a L-amino acid solution prepared for total parenteral nutrition of newborn infants
21. Stability of ceftazidime and amino acids in parenteral nutrient solutions
22. Compatibility of comonly used bone marrow transplant drugs during Y-site delivery
23. Stability of cyclosporine in dextrose 5%, NaCI 0.9%, dextrose/amino acid solution, and lipid emulsion
24. Estabilidad de las mezclas de NP y su compatibilidad de las mezclas de NP y su compatibilidad con fármacos
25. Parenteral nutrient admixtures as drugs vehicles: Theory and practice in the critical care setting
26. Histamine receptor antagonists and lipid stability in total nutrient admixtures
27. Role of histamine (H2)-receptor antagonists in total parenteral nutrition patients
28. Stability of cimetidine in total parenteral nutrition
29. Stability of cimetidine HCI and copper sulfate in a TPN solution
30. Stability of cimetidine hydrochloride in parenteral nutrition solutions
31. Stability of cimetidine hydrochloride in a total nutrient admixtures
32. Estabilidad in vitro de la amikacina y ciprofloxacina administradas en «Y» con dos nutriciones parenterales totales (NPT) de diferentes pH
33. Stability of cisplatin and etoposide in intravenous admixtures
34. Stability of citarabine in a parenteral nutrient solution
35. Compatibility of total nutrient admixtures and secondary cardiovascular medications
36. Stability of human recombinant epoetin alfa in commonly used neonatal intravenous solutions
37. Medication delivery in the short-bowel syndrome
38. Stability of famotidine 20 and 40 mg/l and amino acids in total parenteral nutrient solutions
39. Stability of famotidine 20 and 50 mg/l in total nutrient admixtures
40. Stability of famotidine 20 and 40 mg/l in total nutrient admixtures
41. Long-term stability of famotidine 20 mg/l in a total parenteral nutrient solution
42. Stability of famotidine in a 3-in-1 total nutrient admixtures
43. Stability of fluconazole and amino acids in parenteral nutrient solutions
44. Visual compatibility of foscarnet with other injectable drugs during simulated Y-site administration
45. Stability of ganciclovir sodium and amino acids in parenteral nutrient solutions
46. Pharmacologic levels of heparin do not destabilise neonatal parenteral nutrition
47. Stability of heparin anticoagulant activity over time in parenteral nutrition solutions
48. Compatibility of hydromorphone hydrochloride in large-volume parenterals
49. Stability of imipenem and cilastatina sodium in total parenteral nutrient solutions
50. Stability and activity of intravenous immunoglobulin with neonatal dextrose and total parenteral nutrient solutions
51. Visual compatibility of indometacin sodium trihydrate with drugs given to neonates by continous infusion
52. Availability of insulin from total parenteral nutrition solutions
53. Potential incompatibility of insulin and octreotide in total parenteral nutrient solutions
54. Biological activity of recombinant interleukin-2 in intravenous admixtures containing antibiotic, morphine sulfate, or total parenteral nutrient solution
55. Antibiotic stability in solutions used for intravenous nutrition and fluid therapy
56. Compatibility and stability of electrolytes, vitamins and antibiotics in combination with 8% amino acids solution
57. Flagyl i.v. drug-drug physical compatibility
58. Stability of penicillins in total parenteral nutrient solution
59. Stability of midazolam hydrochloride in parenteral nutrient solutions
60. Stability of morphine and meperidine hydrochloride in a parenteral nutrient formulation
61. Stability of nizatidine in total nutrient admixtures
62. Stability of ondasetron hydrochloride in a total parenteral nutrient admixtures
63. Stability of propofol with parenteral nutrient solutions during simulated Y-site injection
64. Factors influencing the stability of ranitidine in TPN mixtures
65. Stability of ranitidine and thiamine in parenteral nutrition solutions
66. In vitro evaluation of the stability of ranitidine hydrochloride in total parenteral nutrient mixtures
67. Stability of ranitidine hydrochloride in total parenteral nutrient solution
68. Stability of somatostatin in total parenteral nutrition
69. Estabilidad de somatostatina en unidades nutrientes parenterales
70. Stability of tacrolimus injection in total parenteral nutrition solution
71. Stability and compatibility of teicoplanin in parenteral nutrition solutions used in pediatrics
72. Estabilidad de la teofilina en bolsas de nutrición parenteral unicapa y multicapa
73. Compatibility of thiotepa (lyophilized) with selected drugs during simulated Y-site administration
74. The stability of amikacin, gentamicin, and tobramicin in total nutrient admixtures
75. Stability of urokinase in parenteral nutrition solutions
76. In vitro assessment of vancomycin HCl compatibility after coinfusion with a specialised amino acid formulation
77. Stability of vancomycin hydrochloride in total parenteral nutrient solutions
78. Stability and delivery of vancomycin hydrochloride when admixed in a total parenteral nutrition solution
79. Vancomycin stability in heparin and total parenteral nutrition solutions: Novel approach to therapy of central venous catheter-related infections